86 related articles for article (PubMed ID: 22855071)
1. Transsphenoidal surgery for microprolactinomas in women: results and prognosis.
Tamasauskas A; Sinkunas K; Bunevicius A; Radziunas A; Skiriute D; Deltuva VP
Acta Neurochir (Wien); 2012 Oct; 154(10):1889-93. PubMed ID: 22855071
[TBL] [Abstract][Full Text] [Related]
2. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal.
Huda MS; Athauda NB; Teh MM; Carroll PV; Powrie JK
Clin Endocrinol (Oxf); 2010 Apr; 72(4):507-11. PubMed ID: 19549247
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
4. [Transsphenoidal surgery for prolactinomas: results and prognosis].
Sinkūnas K; Rastenyte D; Deltuva VP; Knispelis R; Tamasauskas A
Medicina (Kaunas); 2007; 43(9):691-7. PubMed ID: 17986841
[TBL] [Abstract][Full Text] [Related]
5. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Biswas M; Smith J; Jadon D; McEwan P; Rees DA; Evans LM; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2005 Jul; 63(1):26-31. PubMed ID: 15963057
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
7. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
10. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
11. Microprolactinomas in males treated by transsphenoidal surgery.
Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
13. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
14. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M; Souteiro P; Carvalho D
Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
[TBL] [Abstract][Full Text] [Related]
15. Prolactin Secreting Pituitary Microadenoma: Results of Transsphenoidal Surgery After Medical Therapy With Dopamine Agonist.
Fraioli MF; Umana G; Pagano A; Fraioli B; Lunardi P
J Craniofac Surg; 2017 Jun; 28(4):992-994. PubMed ID: 28277481
[TBL] [Abstract][Full Text] [Related]
16. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
Turner HE; Adams CB; Wass JA
Eur J Endocrinol; 1999 Jan; 140(1):43-7. PubMed ID: 10037250
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic Transnasal Approach for Microprolactinomas with Experience of 105 Cases in a Single Center: Paradigmal Shift for Conventional Medical Therapy.
Uzuner A; Yilmaz E; Caklili M; Selek A; Aydemir F; Cabuk B; Anik I; Ceylan S
World Neurosurg; 2023 Feb; 170():e858-e867. PubMed ID: 36481446
[TBL] [Abstract][Full Text] [Related]
19. Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases.
Sinha S; Sharma BS; Mahapatra AK
Neurol India; 2011; 59(4):532-6. PubMed ID: 21891928
[TBL] [Abstract][Full Text] [Related]
20. THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature.
Tampourlou M; Trifanescu R; Paluzzi A; Ahmed SK; Karavitaki N
Eur J Endocrinol; 2016 Sep; 175(3):R89-96. PubMed ID: 27207245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
